Stockreport

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

Alto Neuroscience, Inc.  (ANRO) 
PDF – ALTO-101, a novel PDE4 inhibitor, has demonstrated pro-cognitive effects in healthy volunteers –– Designation highlights the significant unmet need for new treatments [Read more]